Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Notes Payables: 2010-2024

Historic Notes Payables for China Pharma Holdings (CPHI) over the last 10 years, with Dec 2024 value amounting to $1.1 million.

  • China Pharma Holdings' Notes Payables rose 348.07% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 348.07%. This contributed to the annual value of $1.1 million for FY2024, which is 0.99% up from last year.
  • As of FY2024, China Pharma Holdings' Notes Payables stood at $1.1 million, which was up 0.99% from $1.1 million recorded in FY2023.
  • In the past 5 years, China Pharma Holdings' Notes Payables registered a high of $3.8 million during FY2022, and its lowest value of $1.1 million during FY2023.
  • Its 3-year average for Notes Payables is $2.0 million, with a median of $1.1 million in 2024.
  • Per our database at Business Quant, China Pharma Holdings' Notes Payables soared by 222.25% in 2022 and then slumped by 70.16% in 2023.
  • Yearly analysis of 4 years shows China Pharma Holdings' Notes Payables stood at $1.2 million in 2021, then spiked by 222.25% to $3.8 million in 2022, then crashed by 70.16% to $1.1 million in 2023, then climbed by 0.99% to $1.1 million in 2024.